Twelve Months Ended December 31, 2008 and 2007
(Unaudited)
(Expressed in U.S. Dollars)
Three Months ended Twelve months ended
December 31, December 31,
2008 2007 2008 2007
Cash flows from (used in)
operating activities
Net income (loss) $2,374,140 $1,993,275 $8,010,224 $7,650,406
Adjustments to
reconcile net loss
to net cash provided
(used) by operating
activities:
- deferred income
taxes 504,450 (287,751) (487,011) (229,055)
- stock-based
compensation 16,635 20,595 66,542 179,742
- inventory
provision 1,027,675 373,473 1,027,675 373,473
- provision for
doubtful
accounts (1,944,595) (1,326,175) 23,612 455,674
- written-off
equipment and
loss on disposal 123,987 (938) 126,236 4,016
- amortization of
government
grants (162,345) (478,164) (310,022) (843,910)
- depreciation of
property, plant
and equipment
and amortization
of licenses
and permits 390,704 352,617 1,689,018 1,401,892
- minority
interest 1,390,704 964,588 4,205,407 3,562,501
Change in other assets
and liabilities
- accounts
receivable 7,284,649 4,370,035 (1,366,183) (6,774,082)
- inventories (471,226) 855,096 (4,405,982) (1,832,193)
- income tax
refundable (342,617) -- (342,617) --
- prepaid
expenses and
deposits 40,618 (184,588) 229,407
'/>"/>SOURCE Sinovac Biotech Ltd. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1.
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results2.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results3.
Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status4.
Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility5.
Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine6.
Sinovac Releases Statement on Healive Vaccine Suspension7.
Sinovac Reports Third Quarter 2008 Unaudited Financial Results8.
Sinovac Named to Deloitte Technology Fast 50 China9.
Sinovac to Participate in Two Upcoming Investor Conferences10.
Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating11.
Sinovac Biotech Holds 2007 Annual General Meeting